gorodenkoff/iStock via Getty Images Ipsen ( OTCPK:IPSEY ) Tuesday confirmed the expanded collaboration and license agreement with Exelixis, for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors. The agreement is based on positive outcomes from the CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology, which investigated Cabometyx versus placebo in people living with advanced pNETs or advanced epNETs whose disease had progressed after prior systemic therapy. Ipsen ( OTCPK:IPSEY ) has engaged with regulatory authorities in the European Union and will submit a regulatory filing based on these data.
“With many people diagnosed with neuroendocrine tumors at an advanced stage of disease and treatment options limited upon progression, the need for efficacious new therapies is extensive,” said Christelle Huguet, EVP and Head of Research and Development, Ipsen. Source: Press Release More on Ipsen S.A.
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen gains accelerated approval for elafibranor for rare liver disease Ipsen and Marengo Therapeutics announce second strategic partnership Historical earnings data for Ipsen S.A. Dividend scorecard for Ipsen S.
A..
